Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | HTR1A | P08908 | 3/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | MC5R | P33032 | 1/20 | 0.62 |
| ▸ | MC3R | P41968 | 1/20 | 0.62 |
| ▸ | MC1R | Q01726 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | G6PD | P11413 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30536673 | 1.00 | HTR2A (0.69) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| Bromide SCHEMBL26186699 | 0.98 | HTR2A (0.67) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| Hydrochloric Acid SCHEMBL26688729 | 0.98 | HTR2A (0.67) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL19411654 | 0.91 | KDM4E (0.61) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL3241389 | 0.88 | HTR2A (0.61) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| Fumaric Acid SCHEMBL26688720 | 0.88 | HTR1A (0.64) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL21781048 | 0.88 | KDM4E (0.65) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL11828168 | 0.86 | HTR2A (0.64) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL13652758 | 0.85 | KDM4E (0.61) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL15130901 | 0.85 | KMT2A (0.74) | HTR2AKDM4EALDH1A1HTR1AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4507692-A2 | TRYPTAMINE DERIVATIVES | Caamtech, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2023225679-A2 | N-ISOPROPYL TRYPTAMINES AND METHOD OF MAKING MONOALKYLATED AND DIALKYLATED TRYPTAMINE ANALOGS | CAAMTECH, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| WO-2023201293-A2 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. (US) | 2023-10-19 | — | — | WO | claimed |
| EP-4208177-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | Yztherapeutic Performance Ltd. (IL) | 2023-07-12 | — | — | EP | claimed |
| WO-2021108911-A1 | USE OF PSILOCIN, PSILOCYBIN OR ANALOGS THEREOF IN WEIGHT LOSS, TREATMENT OF OBESITY AND COMPULSIVE EATING DISORDER | NEONMIND BIOSCIENCES INC. (CA) | 2021-06-10 | — | — | WO | claimed |
| CN-112105734-A | Method for producing tryptamine | 新图集生物技术有限责任公司 | 2020-12-18 | — | — | CN | claimed |
| US-20200375967-A1 | COMPOSITIONS OF PSILOCYBIN AND ANALOGS | TURTLE BEAR HOLDINGS, LLC | 2020-12-03 | — | — | US | claimed |
| CN-106581738-A | Superabsorbent medical composite haemostasis sponge and preparation method thereof | 苏州纳贝通环境科技有限公司 | 2017-04-26 | — | — | CN | claimed |
| US-20250129022-A1 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20250129022-A1 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-4507692-A2 | TRYPTAMINE DERIVATIVES | Caamtech, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4507692-A2 | TRYPTAMINE DERIVATIVES | Caamtech, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HTR2A 4267/4885KDM4E 258/4885ALDH1A1 680/4885 |
| US-20200375967-A1 | COMPOSITIONS OF PSILOCYBIN AND ANALOGS | PNMT, NES, GAP43 | HTR2A 97/4885KDM4E 3272/4885ALDH1A1 3982/4885 |
| US-20250129022-A1 | TRYPTAMINE DERIVATIVES | INMT, SLC6A4, HTR5A | HTR2A 8/4885KDM4E 2149/4885ALDH1A1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.